Table 3. Adverse events in PD-1 and PD-L1 treatment.
| Event | Patients who experienced treatment-related adverse events, No. (%) | ||||
|---|---|---|---|---|---|
| Any grade | Grade ≥3 | ||||
| PD-1 (n=146) | PD-L1 (n=75) | PD-1 (n=146) | PD-L1 (n=75) | ||
| Any treatment-related adverse event | 98 (67.12) | 48 (64.00) | 42 (28.77) | 16 (21.33) | |
| Neutrophil count decreased | 57 (39.04) | 34 (45.33) | 30 (20.55) | 7 (9.33) | |
| White blood cell count decreased | 64 (43.84) | 35 (46.67) | 32 (21.92) | 8 (10.67) | |
| Platelet count decreased | 25 (17.12) | 11 (14.67) | 7 (4.79) | 0 (0) | |
| Anemia | 23 (15.75) | 5 (6.67) | 1 (0.68) | 2 (2.67) | |
| Nausea | 36 (24.66) | 17 (22.67) | 5 (3.42) | 1 (1.33) | |
| Vomiting | 28 (19.18) | 17 (22.67) | 7 (4.79) | 1 (1.33) | |
| Pneumonia | 5 (3.42) | 6 (8.00) | 3 (2.05) | 5 (6.67) | |
| Alanine/aspartate aminotransferase increased | 10 (6.85) | 2 (2.67) | 7 (4.79) | 1 (1.33) | |
PD-1, programmed cell death 1; PD-L1, programmed cell death ligand 1.